2/26
08:58 am
supn
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $36.00 price target on the stock.
Low
Report
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $36.00 price target on the stock.
2/26
08:49 am
supn
Rating for SUPN
Low
Report
Rating for SUPN
2/19
09:50 am
supn
Rating for SUPN
Low
Report
Rating for SUPN
2/19
07:06 am
supn
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating. They now have a $36.00 price target on the stock, down previously from $57.00.
Medium
Report
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating. They now have a $36.00 price target on the stock, down previously from $57.00.
2/18
08:52 pm
supn
Supernus downgraded to Neutral from Overweight at Cantor Fitzgerald
Low
Report
Supernus downgraded to Neutral from Overweight at Cantor Fitzgerald
1/6
08:55 am
supn
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $57.00 price target on the stock.
Low
Report
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $57.00 price target on the stock.
1/6
07:23 am
supn
Supernus initiated with an Overweight at Cantor Fitzgerald
Low
Report
Supernus initiated with an Overweight at Cantor Fitzgerald
1/6
06:20 am
supn
Supernus initiated with an Overweight at Cantor Fitzgerald
Low
Report
Supernus initiated with an Overweight at Cantor Fitzgerald